CENTANOL Tablet
ក្រុមហ៊ុនផលិតឱសថ:
THERAGEN ETEX CO., LTD., Korea
- សារធាតុសកម្ម
- ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
- ហាមប្រើ
- ផលរំខាន
- អន្តរប្រតិកម្ម
- ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
- ការប្រុងប្រយ័ត្នជាពិសេស បរិយាយប័ណ្ណឱសថ
-
សារធាតុសកម្ម
Ranitidine hydrochloride 31.5mg, Magnesium oxide 50mg, Magnesium aluminosilicate 125mg, Magnesium alumminium hydrate 100mg
-
ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
INDICATIONS:
Stomachache, Brash, Dyspepsia and nausea.
DOSAGE AND ADMINISTRATION:
In adults (15-80 years): a single dose of 2 tablets, but if there is no improvement 5 hours after administration, take 2 more tablets.
For adults, a total daily dose should not exceed 4 tablets.
-
ហាមប្រើ
1) Patients under treatment of the following disease blood disease, renal hepatic disease, gastrointestinal disease immune system disorders such as asthma , rheumatism, etc. (occasionally decrease of leukocyte, decrease of platelet, etc. may occur. In case of patients under treatment of gastroduodenal disease, the similar drug to ranitidine may be prescribed, so be careful about double dosage.
2. Patients who are taken the following drugs: steroid, antibiotics, anticancers, azole antifungals, occasionally decreaseof leukocyte, decrease of platelet, etc. may occur. In case of patients who are in treatment of gastroduodenal disease, the similar drug to ranitidine may be prescribed, so be careful about double dosage.
3. patients with history of haematological abnormalities such as leukopeniam thrombocytopenia and erythrocytopenia, reduction of blood count may increase.
4. Patients with history of hypersensitivity with H2-antagonist.
5. Children (under 15 years), elder (over 80 years): the safety in children has not been established (clinical trials are insufficient). In patients more than 80 years of age, a falling-off in renal function may raise blood concentration, may potentiate effect.
6. Patient under dialysis treatment.
-
ផលរំខាន
It rarely may cause symptoms as follows. In this case, discontinue the adminstration and consult a physician or pharmacist immediately.
1. Allergic symptoms (eruption, skin flare, itch, edema). constipation, diarrhea, vomiting headache, dizziness, and myalgia. (there are known as adverse effect symptoms of Ranitidine HCl).
2. In case of immediate appearance of suffocation feeling of cold extremity, and cold sweating after administration of this medicine.
3. In case of appearance of severe symptoms like blister for eruption, skin flare, etc. with hyperpyreixia on general skin, and mucous membrane of lip and neck.
4. Throat ache, febricity, malaise, white coating on face and inside of eyelid, gingival bleeding, nasal bleeding.
5. Jaundice.
-
អន្តរប្រតិកម្ម
1. Absorption of the antacids, which are contained in this medicine, can be impeded for interaction with tetracycline antibiotics, and new-quinolone antimicrobial.
2. Do not use this medicine with other medicine for the stomach and bowels. If it use this medicine with other medicine for the stomach and bowels, unexpected adverse effects may occur for strong interaction.
-
ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
The safety during pregnancy has not been established. And because this drug is excreted into breast milk, it is necessary not to nurse during the use of this drug.
-
ការប្រុងប្រយ័ត្នជាពិសេស
1. If there is no improvement in spite of administration for 3 days, discontineu the administration and consult a physician or pharmacist because there are possbilility of other diseases.
2. Do not continuously use over for 2 weeks.
3. Do not drink alcohol beverage, when taking this medicine.
4. If you take overdose, discontinue the administration and consult a physician or pharmacist.
5. Do not use for indication exception stated indication.
6. Long term therapy is not recommended.
7. Patients with history for renal disease should consult a physician and pharmacist before administration.
*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។
ប្រភពព័ត៌មាន៖
- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp
- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp